Arama Sonuçları - David M. Gershenson

Sonuçları Daraltın
  1. 1
    Update on malignant ovarian germ cell tumors

    Update on malignant ovarian germ cell tumors Yazar: David M. Gershenson

    Baskı/Yayın Bilgisi 1993
    Tam Metin Erişim Tam Metin Erişim
    Revisão
    Favorilerime ekle
    Kaydedildi:
  2. 2
    Fertility-Sparing Surgery for Malignancies in Women

    Fertility-Sparing Surgery for Malignancies in Women Yazar: David M. Gershenson

    Baskı/Yayın Bilgisi 2005
    Tam Metin Erişim Tam Metin Erişim
    Revisão
    Favorilerime ekle
    Kaydedildi:
  3. 3
    Low-grade serous carcinoma of the ovary or peritoneum

    Low-grade serous carcinoma of the ovary or peritoneum Yazar: David M. Gershenson

    Baskı/Yayın Bilgisi 2016
    Tam Metin Erişim Tam Metin Erişim
    Revisão
    Favorilerime ekle
    Kaydedildi:
  4. 4
    Sexual dysfunction and treatment for early stage cervical cancer

    Sexual dysfunction and treatment for early stage cervical cancer Yazar: Leslie R. Schover, Michael Fife, David M. Gershenson

    Baskı/Yayın Bilgisi 1989
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  5. 5
    Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum

    Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum Yazar: David M. Gershenson, Charlotte C. Sun, Kwong‐Kwok Wong

    Baskı/Yayın Bilgisi 2015
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  6. 6
    Unmasking the complexities of mucinous ovarian carcinoma

    Unmasking the complexities of mucinous ovarian carcinoma Yazar: Michael Frumovitz, Kathleen M. Schmeler, Anaís Malpica, Anil K. Sood, David M. Gershenson

    Baskı/Yayın Bilgisi 2010
    Tam Metin Erişim
    Revisão
    Favorilerime ekle
    Kaydedildi:
  7. 7
    Trends of low-grade serous ovarian carcinoma in the United States

    Trends of low-grade serous ovarian carcinoma in the United States Yazar: Koji Matsuo, Hiroko Machida, Brendan H. Grubbs, Anil K. Sood, David M. Gershenson

    Baskı/Yayın Bilgisi 2017
    Tam Metin Erişim
    Carta
    Favorilerime ekle
    Kaydedildi:
  8. 8
    Serous borderline tumors of the ovary with noninvasive peritoneal implants

    Serous borderline tumors of the ovary with noninvasive peritoneal implants Yazar: David M. Gershenson, Elvio G. Silva, Guillermo Tortolero‐Luna, Charles Levenback, Mitchell Morris, Carmen Tornos

    Baskı/Yayın Bilgisi 1998
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  9. 9
    The Activity of Taxanes in the Treatment of Sex Cord-Stromal Ovarian Tumors

    The Activity of Taxanes in the Treatment of Sex Cord-Stromal Ovarian Tumors Yazar: Jubilee Brown, Hyun S. Shvartsman, Michael T. Deavers, Thomas W. Burke, Mark F. Munsell, David M. Gershenson

    Baskı/Yayın Bilgisi 2004
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  10. 10
    MEK inhibitor resistance mechanisms and recent developments in combination trials

    MEK inhibitor resistance mechanisms and recent developments in combination trials Yazar: Eucharist Kun, Yvonne T.M. Tsang, Chun Wai Ng, David M. Gershenson, Kwong‐Kwok Wong

    Baskı/Yayın Bilgisi 2020
    Tam Metin Erişim Tam Metin Erişim
    Revisão
    Favorilerime ekle
    Kaydedildi:
  11. 11
    The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer

    The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer Yazar: Erin K. Crane, Charlotte C. Sun, Pedro T. Ramírez, Kathleen M. Schmeler, Anaís Malpica, David M. Gershenson

    Baskı/Yayın Bilgisi 2014
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  12. 12
    Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001)

    Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001) Yazar: Panagiotis A. Konstantinopoulos, William E. Brady, John Farley, Amy E. Armstrong, Denise Uyar, David M. Gershenson

    Baskı/Yayın Bilgisi 2018
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  13. 13
    Ovarian serous borderline tumors with invasive peritoneal implants

    Ovarian serous borderline tumors with invasive peritoneal implants Yazar: David M. Gershenson, Elvio G. Silva, Lawrence B. Levy, Thomas W. Burke, Judith K. Wolf, Carmen Tornos

    Baskı/Yayın Bilgisi 1998
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  14. 14
    The current status of surgical staging of ovarian serous borderline tumors

    The current status of surgical staging of ovarian serous borderline tumors Yazar: Paul Lin, David M. Gershenson, Michael W. Bevers, Kristin R. Lucas, Thomas W. Burke, Elvio G. Silva

    Baskı/Yayın Bilgisi 1999
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  15. 15
    Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience

    Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience Yazar: Heather J. Dalton, Nicole D. Fleming, Charlotte C. Sun, Priya Bhosale, Kathleen M. Schmeler, David M. Gershenson

    Baskı/Yayın Bilgisi 2017
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  16. 16
    Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum

    Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum Yazar: David M. Gershenson, Diane C. Bodurka, Robert L. Coleman, Karen H. Lu, Anaís Malpica, Charlotte C. Sun

    Baskı/Yayın Bilgisi 2017
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  17. 17
    Subcellular Localization of p27kip1 Expression Predicts Poor Prognosis in Human Ovarian Cancer

    Subcellular Localization of p27kip1 Expression Predicts Poor Prognosis in Human Ovarian Cancer Yazar: Daniel Rosen, Gong Yang, Kathy Q. Cai, Robert C. Bast, David M. Gershenson, Elvio G. Silva, Jinsong Liu

    Baskı/Yayın Bilgisi 2005
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  18. 18
    Prognosis of surgically determined complete responders in advanced ovarian cancer

    Prognosis of surgically determined complete responders in advanced ovarian cancer Yazar: David M. Gershenson, Larry J. Copeland, Taylor Wharton, E. Neely Atkinson, Nour Sneige, Creighton L. Edwards, Felix N. Rutledge

    Baskı/Yayın Bilgisi 1985
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  19. 19
    Survival in Women With Grade 1 Serous Ovarian Carcinoma

    Survival in Women With Grade 1 Serous Ovarian Carcinoma Yazar: Amanda N. Fader, James Java, Stefanie Ueda, Robert E. Bristow, Deborah K. Armstrong, Michael A. Bookman, David M. Gershenson

    Baskı/Yayın Bilgisi 2013
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  20. 20
    ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells

    ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells Yazar: Tsz-Lun Yeung, Cecilia S. Leung, Kwong‐Kwok Wong, Arthur Gutierrez‐Hartmann, Joseph Kwong, David M. Gershenson, Samuel C. Mok

    Baskı/Yayın Bilgisi 2017
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:

Arama Araçları: